• Citer

Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

par Bartlett, John M S;Poole, Christopher;Shepherd, Lois;Cardoso, Fatima ;Jensen, Maj Britt;Caldas, Carlos;Twelves, Chris;Rea, Daniel William;Ejlertsen, Bent;Leo, Angelo;Pritchard, Kathleen;McConkey, Christopher C.C.;Munro, Alison;Desmedt, Christine ;Dunn, Janet J.A.;Larsimont, Denis ;O'Malley, Frances Philomena;Cameron, David D.A.;Earl, Helena
Référence Journal of clinical oncology, 33, 15, page (1680-1687)
Publication Publié, 2015-05

Article révisé par les pairs

• Détails
• Contenu

Titre:	Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also
Auteur:	Bartlett, John M S; Poole, Christopher; Shepherd, Lois; Cardoso, Fatima; Jensen, Maj Britt; Caldas, Carlos; Twelves, Chris; Rea, Daniel William; Ejlertsen, Bent; Leo, Angelo; Pritchard, Kathleen; McConkey, Christopher C.C.; Munro, Alison; Desmedt, Christine; Dunn, Janet J.A.; Larsimont, Denis; O'Malley, Frances Philomena; Cameron, David D.A.; Earl, Helena
Informations sur la publication:	Journal of clinical oncology, 33, 15, page (1680-1687)
Statut de publication:	Publié, 2015-05
Sujet CREF:	Cancérologie
MeSH keywords:	Anthracyclines -- therapeutic use
	Antigens, Neoplasm -- genetics
	Antineoplastic Agents -- therapeutic use
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Biomarkers, Tumor
	Centromere -- chemistry
	Chromosomes, Human, Pair 17 -- genetics
	Clinical Trials, Phase III as Topic
	Cyclophosphamide -- therapeutic use
	DNA Topoisomerases, Type II -- genetics
	DNA-Binding Proteins -- genetics
	Disease-Free Survival
	Fluorescent Dyes -- chemistry
	Fluorouracil -- therapeutic use
	Genetic Markers
	Humans
	In Situ Hybridization, Fluorescence
	Methotrexate -- therapeutic use
	Neoplasm Recurrence, Local
	Neoplasms -- drug therapy -- genetics
	Prognosis
	Proportional Hazards Models
	Treatment Outcome
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2013.54.7869
	info:pii/JCO.2013.54.7869
	info:scp/84933575890
	info:pmid/25897160